| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8669237 | The Journal of Heart and Lung Transplantation | 2018 | 8 Pages |
Abstract
This pilot study suggests low-intensity anti-coagulation targeting an INR between 1.5 and 1.9 is achievable and safe with the HeartMate 3 cardiac pump in the short-term phase, 6-months post-implant. A large-scale trial is now warranted.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Ivan MD, PhD, Peter MD, PhD, Zuzana MD, Stanislav PharmD, Ondrej MD, PhD, Poornima MD, Daniel PhD, Jessica PharmD, BCPS, Jean Marie MD, Mandeep R. MD,